National expansion GoPath Diagnostics is actively expanding through national collaborations and hospital partnerships, including a new national agreement with Capstone Health Alliance. This suggests sales opportunities around hospital network access, centralized testing programs, and integrated diagnostic solutions for large health systems.

Exclusive test rights The exclusive U.S. rights partnership for OncoAssure Prostate positions GoPath as a preferred provider for specialized prostate testing. This creates upsell potential with urology clinics, oncology groups, and hospital laboratories seeking differentiated molecular assays.

Strategic research collaborations Recent USCAP presentations with Celnovte Biotechnology on comprehensive biomarker profiling indicate a focus on precision oncology. This opens opportunities to collaborate on biomarker-driven clinical trials, companion diagnostics, and payer-backed diagnostic pathways.

Integrated AI and digital pathology Past collaborations to integrate AI with GoPath’s digital pathology platform signal readiness for AI-assisted diagnostic services and clinical trial analytics. Prospects include pharma trials, CRO partnerships, and healthcare systems seeking scalable imaging analytics.

Broad service portfolio GoPath offers a wide range of technologies (IHC, FISH, PCR, flow cytometry, cytogenetics, micro-array, NGS) and services that can address diverse hospital lab needs. This creates cross-sell potential across departments such as oncology, pathology, genetics, and transfusion medicine, especially in centers migrating to comprehensive molecular diagnostics.